Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT

OBJECTIVE: ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine measures of β-cell function...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahn, Steven E., Lachin, John M., Zinman, Bernard, Haffner, Steven M., Aftring, R. Paul, Paul, Gitanjali, Kravitz, Barbara G., Herman, William H., Viberti, Giancarlo, Holman, Rury R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Pathophysiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292330/
https://www.ncbi.nlm.nih.gov/pubmed/21415383
http://dx.doi.org/10.2337/db10-1392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292330/
https://www.ncbi.nlm.nih.gov/pubmed/21415383
http://dx.doi.org/10.2337/db10-1392

Ejemplares similares